{"id":"c5-inhibitor","safety":{"commonSideEffects":[{"rate":null,"effect":"Meningococcal infection"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"C5 inhibitors target the complement system, a key part of innate immunity. By blocking C5 cleavage, these agents prevent generation of C5a (a potent inflammatory mediator) and C5b-9 (the membrane attack complex). This reduces complement-mediated inflammation and cell lysis in diseases driven by excessive complement activation.","oneSentence":"A C5 complement inhibitor blocks the activation of the C5 component of the complement cascade, preventing formation of the membrane attack complex and reducing inflammatory cell activation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:38.067Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Paroxysmal nocturnal hemoglobinuria (PNH)"},{"name":"Atypical hemolytic uremic syndrome (aHUS)"},{"name":"Generalized myasthenia gravis (gMG)"},{"name":"C3 glomerulopathy"}]},"trialDetails":[{"nctId":"NCT04958265","phase":"PHASE3","title":"A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-11-17","conditions":"Atypical Hemolytic Uremic Syndrome","enrollment":41},{"nctId":"NCT07154745","phase":"PHASE3","title":"A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-03-31","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":35},{"nctId":"NCT05536297","phase":"PHASE3","title":"Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2022-09-26","conditions":"Geographic Atrophy, Age-Related Macular Degeneration","enrollment":278},{"nctId":"NCT07187401","phase":"PHASE1, PHASE2","title":"A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-02-11","conditions":"Paroxysmal Nocturnal Hemoglobinuria (PNH), Persistent Anemia","enrollment":24},{"nctId":"NCT05389449","phase":"PHASE3","title":"A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2022-10-28","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":80},{"nctId":"NCT07470762","phase":"PHASE1, PHASE2","title":"Study of Safety and Efficacy of HS-10542 in Patients With Paroxysmal Nocturnal Hemoglobinuria","status":"RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2026-02-14","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":50},{"nctId":"NCT03364153","phase":"PHASE2","title":"Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-01-12","conditions":"Stargardt's Macular Dystrophy","enrollment":121},{"nctId":"NCT07221838","phase":"PHASE4","title":"A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab","status":"NOT_YET_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2026-02-27","conditions":"Generalized Myasthenia Gravis, gMG","enrollment":75},{"nctId":"NCT05133531","phase":"PHASE3","title":"A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-08-01","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":190},{"nctId":"NCT07250750","phase":"PHASE1, PHASE2","title":"A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis","status":"RECRUITING","sponsor":"ImmunAbs Inc.","startDate":"2026-02-05","conditions":"Myasthenia Gravis","enrollment":96},{"nctId":"NCT05966467","phase":"","title":"Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2024-02-01","conditions":"Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD","enrollment":122},{"nctId":"NCT06052839","phase":"PHASE2","title":"Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC","status":"RECRUITING","sponsor":"Dan Zandberg","startDate":"2023-10-03","conditions":"Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)","enrollment":15},{"nctId":"NCT04861259","phase":"PHASE3","title":"A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-22","conditions":"Atypical Hemolytic Uremic Syndrome","enrollment":83},{"nctId":"NCT06931691","phase":"","title":"A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-06-10","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":80},{"nctId":"NCT07256301","phase":"PHASE1","title":"A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)","status":"RECRUITING","sponsor":"Shanghai Lanyi Therapeutics Co., Ltd.","startDate":"2024-01-03","conditions":"PNH - Paroxysmal Nocturnal Hemoglobinuria","enrollment":24},{"nctId":"NCT05482893","phase":"PHASE1, PHASE2","title":"Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)","status":"RECRUITING","sponsor":"Phanes Therapeutics","startDate":"2023-03-15","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)","enrollment":258},{"nctId":"NCT04435366","phase":"PHASE3","title":"A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)","status":"COMPLETED","sponsor":"IVERIC bio, Inc.","startDate":"2020-06-22","conditions":"Geographic Atrophy, Macular Degeneration","enrollment":448},{"nctId":"NCT05972967","phase":"PHASE2","title":"Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab","status":"COMPLETED","sponsor":"Omeros Corporation","startDate":"2023-03-27","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":12},{"nctId":"NCT07184840","phase":"PHASE2","title":"Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder","status":"RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2025-09-09","conditions":"Neuromyelitis Optica Spectrum Disorder Attack","enrollment":110},{"nctId":"NCT06673394","phase":"PHASE2","title":"Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder","status":"WITHDRAWN","sponsor":"Tianjin Medical University General Hospital","startDate":"2025-09-03","conditions":"Neuromyelitis Optica Spectrum Disorder Attack","enrollment":""},{"nctId":"NCT06903130","phase":"","title":"Clinical Study to Evaluate the Effects of the Complement C5 Inhibitor Ravulizumab on Serum Neurofilament Light Chain (sNfL) and Glial Fibrillary Acidic Protein (sGFAP) Levels in Patients With Aquaporin-4-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD)","status":"NOT_YET_RECRUITING","sponsor":"National and Kapodistrian University of Athens","startDate":"2025-09-01","conditions":"NMOSD","enrollment":40},{"nctId":"NCT03362190","phase":"PHASE2","title":"ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)","status":"COMPLETED","sponsor":"Ophthotech Corporation","startDate":"2017-10-11","conditions":"Neovascular Age-related Macular Degeneration","enrollment":64},{"nctId":"NCT02686658","phase":"PHASE2, PHASE3","title":"Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"IVERIC bio, Inc.","startDate":"2015-12-15","conditions":"Geographic Atrophy, Dry Age-Related Macular Degeneration","enrollment":286},{"nctId":"NCT04469465","phase":"PHASE3","title":"Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-12-16","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":86},{"nctId":"NCT04702568","phase":"PHASE2","title":"A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)","status":"TERMINATED","sponsor":"BioCryst Pharmaceuticals","startDate":"2020-12-18","conditions":"Paroxysmal Nocturnal Hemoglobinuria, PNH","enrollment":19},{"nctId":"NCT05061771","phase":"PHASE3","title":"Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)","status":"WITHDRAWN","sponsor":"AKARI Therapeutics","startDate":"2022-05-06","conditions":"Bullous Pemphigoid","enrollment":""},{"nctId":"NCT05116774","phase":"PHASE2","title":"BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy","status":"TERMINATED","sponsor":"BioCryst Pharmaceuticals","startDate":"2021-12-06","conditions":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":12},{"nctId":"NCT04170023","phase":"PHASE2","title":"Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy","status":"TERMINATED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2019-12-16","conditions":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","enrollment":29},{"nctId":"NCT06311448","phase":"","title":"Personalized Targeted Immunomodulation in COVID-19 ARDS","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2020-03-02","conditions":"COVID-19 Acute Respiratory Distress Syndrome","enrollment":164},{"nctId":"NCT03374670","phase":"PHASE2","title":"ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)","status":"WITHDRAWN","sponsor":"Ophthotech Corporation","startDate":"2018-11","conditions":"Idiopathic Polypoidal Choroidal Vasculopathy","enrollment":""},{"nctId":"NCT05539248","phase":"PHASE1, PHASE2","title":"A Study on the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 in Subjects With PNH","status":"UNKNOWN","sponsor":"CARE Pharma Shanghai Ltd.","startDate":"2022-03-25","conditions":"PNH, Hemolysis","enrollment":78},{"nctId":"NCT05095168","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) of CAN106 Administered Intravenously (IV) in Healthy Subjects","status":"COMPLETED","sponsor":"CARE Pharma Shanghai Ltd.","startDate":"2021-02-22","conditions":"PNH","enrollment":31},{"nctId":"NCT05374252","phase":"PHASE3","title":"Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2022-05-07","conditions":"Anal Canal Cancer Stage III, Anal Squamous Cell Carcinoma, Anal Canal Cancer","enrollment":102},{"nctId":"NCT03500549","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)","status":"COMPLETED","sponsor":"Apellis Pharmaceuticals, Inc.","startDate":"2018-06-14","conditions":"Paroxysmal Nocturnal Hemoglobinuria","enrollment":80},{"nctId":"NCT04802083","phase":"","title":"COVID-19 Soliris Expanded Access Protocol","status":"NO_LONGER_AVAILABLE","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"","conditions":"Covid19","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":297,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"C5 Inhibitor","genericName":"C5 Inhibitor","companyName":"Alexion Pharmaceuticals, Inc.","companyId":"alexion-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A C5 complement inhibitor blocks the activation of the C5 component of the complement cascade, preventing formation of the membrane attack complex and reducing inflammatory cell activation. Used for Paroxysmal nocturnal hemoglobinuria (PNH), Atypical hemolytic uremic syndrome (aHUS), Generalized myasthenia gravis (gMG).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}